Cargando…
Influenza
Influenza is an infectious respiratory disease that, in humans, is caused by influenza A and influenza B viruses. Typically characterized by annual seasonal epidemics, sporadic pandemic outbreaks involve influenza A virus strains of zoonotic origin. The WHO estimates that annual epidemics of influen...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097467/ https://www.ncbi.nlm.nih.gov/pubmed/29955068 http://dx.doi.org/10.1038/s41572-018-0002-y |
_version_ | 1783511005722050560 |
---|---|
author | Krammer, Florian Smith, Gavin J. D. Fouchier, Ron A. M. Peiris, Malik Kedzierska, Katherine Doherty, Peter C. Palese, Peter Shaw, Megan L. Treanor, John Webster, Robert G. García-Sastre, Adolfo |
author_facet | Krammer, Florian Smith, Gavin J. D. Fouchier, Ron A. M. Peiris, Malik Kedzierska, Katherine Doherty, Peter C. Palese, Peter Shaw, Megan L. Treanor, John Webster, Robert G. García-Sastre, Adolfo |
author_sort | Krammer, Florian |
collection | PubMed |
description | Influenza is an infectious respiratory disease that, in humans, is caused by influenza A and influenza B viruses. Typically characterized by annual seasonal epidemics, sporadic pandemic outbreaks involve influenza A virus strains of zoonotic origin. The WHO estimates that annual epidemics of influenza result in ~1 billion infections, 3–5 million cases of severe illness and 300,000–500,000 deaths. The severity of pandemic influenza depends on multiple factors, including the virulence of the pandemic virus strain and the level of pre-existing immunity. The most severe influenza pandemic, in 1918, resulted in >40 million deaths worldwide. Influenza vaccines are formulated every year to match the circulating strains, as they evolve antigenically owing to antigenic drift. Nevertheless, vaccine efficacy is not optimal and is dramatically low in the case of an antigenic mismatch between the vaccine and the circulating virus strain. Antiviral agents that target the influenza virus enzyme neuraminidase have been developed for prophylaxis and therapy. However, the use of these antivirals is still limited. Emerging approaches to combat influenza include the development of universal influenza virus vaccines that provide protection against antigenically distant influenza viruses, but these vaccines need to be tested in clinical trials to ascertain their effectiveness. |
format | Online Article Text |
id | pubmed-7097467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-70974672020-03-26 Influenza Krammer, Florian Smith, Gavin J. D. Fouchier, Ron A. M. Peiris, Malik Kedzierska, Katherine Doherty, Peter C. Palese, Peter Shaw, Megan L. Treanor, John Webster, Robert G. García-Sastre, Adolfo Nat Rev Dis Primers Primer Influenza is an infectious respiratory disease that, in humans, is caused by influenza A and influenza B viruses. Typically characterized by annual seasonal epidemics, sporadic pandemic outbreaks involve influenza A virus strains of zoonotic origin. The WHO estimates that annual epidemics of influenza result in ~1 billion infections, 3–5 million cases of severe illness and 300,000–500,000 deaths. The severity of pandemic influenza depends on multiple factors, including the virulence of the pandemic virus strain and the level of pre-existing immunity. The most severe influenza pandemic, in 1918, resulted in >40 million deaths worldwide. Influenza vaccines are formulated every year to match the circulating strains, as they evolve antigenically owing to antigenic drift. Nevertheless, vaccine efficacy is not optimal and is dramatically low in the case of an antigenic mismatch between the vaccine and the circulating virus strain. Antiviral agents that target the influenza virus enzyme neuraminidase have been developed for prophylaxis and therapy. However, the use of these antivirals is still limited. Emerging approaches to combat influenza include the development of universal influenza virus vaccines that provide protection against antigenically distant influenza viruses, but these vaccines need to be tested in clinical trials to ascertain their effectiveness. Nature Publishing Group UK 2018-06-28 2018 /pmc/articles/PMC7097467/ /pubmed/29955068 http://dx.doi.org/10.1038/s41572-018-0002-y Text en © Macmillan Publishers Ltd., part of Springer Nature 2018 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Primer Krammer, Florian Smith, Gavin J. D. Fouchier, Ron A. M. Peiris, Malik Kedzierska, Katherine Doherty, Peter C. Palese, Peter Shaw, Megan L. Treanor, John Webster, Robert G. García-Sastre, Adolfo Influenza |
title | Influenza |
title_full | Influenza |
title_fullStr | Influenza |
title_full_unstemmed | Influenza |
title_short | Influenza |
title_sort | influenza |
topic | Primer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097467/ https://www.ncbi.nlm.nih.gov/pubmed/29955068 http://dx.doi.org/10.1038/s41572-018-0002-y |
work_keys_str_mv | AT krammerflorian influenza AT smithgavinjd influenza AT fouchierronam influenza AT peirismalik influenza AT kedzierskakatherine influenza AT dohertypeterc influenza AT palesepeter influenza AT shawmeganl influenza AT treanorjohn influenza AT websterrobertg influenza AT garciasastreadolfo influenza |